CSF ACR 2022 - Congress Preview (RA)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Key Presentations<br />
Editor’s Picks<br />
Saturday, 12 November <strong>2022</strong><br />
13:00–<br />
15:00<br />
1648<br />
16:00–<br />
16:10<br />
510<br />
13:00–<br />
15:00<br />
0198<br />
13:00–<br />
15:00<br />
0046<br />
13:00–<br />
15:00<br />
0267<br />
13:00–<br />
15:00<br />
0296<br />
0272<br />
0273<br />
0275<br />
POSTER SESSION<br />
<strong>RA</strong> – DIAGNOSIS, MANIFESTATIONS,<br />
AND OUTCOMES<br />
Risk of Vascular Events Under the Treatments with Janus<br />
Kinase Inhibitors in Patients with Rheumatoid Arthritis: An<br />
Analysis Using Japanese Health Insurance Database<br />
Eiichi Tanaka<br />
O<strong>RA</strong>L SESSION<br />
MISCELLANEOUS RHEUMATIC AND INFLAMMATORY<br />
DISEASES I<br />
MACE and VTE Across Upadacitinib Clinical Trial Programs<br />
in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing<br />
Spondylitis<br />
Christina Charles-Schoeman<br />
POSTER SESSION<br />
PATIENT OUTCOMES, PREFERENCES, AND<br />
ATTITUDES POSTER I<br />
Patient Perspectives on Janus Kinase Inhibitor Use in the<br />
Treatment of Inflammatory Arthritis<br />
Savia de Souza<br />
POSTER SESSION<br />
<strong>RA</strong> – ANIMALS MODELS POSTER<br />
Baricitinib Ameliorates Residual Neuropathic Pain in Collagen<br />
Antibody-Induced Arthritis Mice by Suppressing Inflammation<br />
of the Dorsal Root Ganglion<br />
Kenta Makabe<br />
POSTER SESSION<br />
<strong>RA</strong> – DIAGNOSIS, MANIFESTATION AND OUTCOMES<br />
POSTER I<br />
Cancer Risk with Biologic and Targeted Synthetic DMARDs in<br />
Patients with Rheumatic Diseases and Previous Malignancy:<br />
Results from the BIOBADASER Register<br />
Juan Molina<br />
POSTER SESSION<br />
<strong>RA</strong> – TREATMENT POSTER I<br />
Characteristics and Treatment-selection in Patients with<br />
Rheumatoid Arthritis and with Inadequate Response to Janus<br />
Kinase Inhibitors<br />
Yusuke Miyazaki<br />
Long-Term Efficacy of Baricitinib in Patients with Rheumatoid<br />
Arthritis with Inadequate Response to Bdmards: Results from<br />
<strong>RA</strong>-BEYOND up to 6.9-Years of Treatment<br />
Roberto Caporali & Daniel Aletaha<br />
An Update on the Integrated Safety Analysis of Filgotinib in<br />
Patients with Moderately to Severely Active <strong>RA</strong><br />
Kevin Winthrop<br />
Exploratory Analysis of Filgotinib Safety Data in Patients with<br />
Moderately to Severely Active <strong>RA</strong> and an Increased Risk of<br />
Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials<br />
Maya Buch<br />
0277<br />
274<br />
0282<br />
0286<br />
0293<br />
0294<br />
0295<br />
0297<br />
0299<br />
0304<br />
0274<br />
0276<br />
0279<br />
Malignancy Events in the Filgotinib Rheumatoid Arthritis and<br />
Ulcerative Colitis Clinical Development Programs<br />
Xavier Mariette<br />
Clinical Outcomes of Filgotinib in Patients with <strong>RA</strong> Aged ≥65<br />
Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical<br />
Trials and Ongoing Long-Term Extensions<br />
Maya Buch<br />
Efficacy and Safety of Upadacitinib in TNFi-IR Patients with<br />
Rheumatoid Arthritis from Three Phase 3 Clinical Trials<br />
Roy Fleischmann<br />
Efficacy and Safety of Upadacitinib in Patients Across Races<br />
with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3<br />
Clinical Trials<br />
Grace Wright<br />
Long-term Sustainability of Response to Upadacitinib Among<br />
Patients with Active Rheumatoid Arthritis Refractory to<br />
Biological Disease-Modifying Anti-Rheumatic Drugs: Results<br />
Through 5 Years from SELECT-BEYOND<br />
Ronald van Vollenhoven<br />
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid<br />
Arthritis and Inadequate Response or Intolerance to Biologic<br />
DMARDs: Results Through 5 Years from the SELECT-BEYOND<br />
Study<br />
Roy Fleischmann<br />
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid<br />
Arthritis and Inadequate Response to Conventional Synthetic<br />
DMARDs: Results Through 5 Years from the SELECT-NEXT<br />
Study<br />
Gerd Burmester<br />
Effect of Upadacitinib, Adalimumab, and Placebo on Residual<br />
Pain Among Patients with Rheumatoid Arthritis Whose<br />
Inflammation Was Attenuated After Three and Six Months of<br />
Treatment<br />
Louis Bessette<br />
Radiographic Change in Patients with Rheumatoid Arthritis and<br />
Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc<br />
Analysis of Two Phase 3 Trials of Filgotinib<br />
Yoshiya Tanaka<br />
Rheumatoid Arthritis Patients Who Switched Treatment from<br />
Adalimumab to Upadacitinib Demonstrate a Robust Reduction<br />
of Inflammation-related Biomarkers: Proteomics Analysis from<br />
the SELECT-COMPARE Phase 3 Study<br />
Thierry Sornasse<br />
Real-world Utilisation and Switching Between Janus Kinase<br />
Inhibitors in Patients with Rheumatoid Arthritis in the Australian<br />
OPAL Dataset<br />
Sabina Ciciriello<br />
Baseline Characteristics of and Early Outcomes in the First<br />
200 Patients with <strong>RA</strong> Treated with Filgotinib in a Prospective<br />
Observational Study<br />
James Galloway<br />
Effect of Filgotinib on Body Weight and BMI and Effect of<br />
Baseline BMI on the Efficacy and Safety of Filgotinib in <strong>RA</strong><br />
Alejandro Balsa
Change language